Those of you with a family history of cancer may wonder about your own risk of developing cancer. One third of the population will develop cancer, and 5-10% of all cancers are hereditary. Understanding your hereditary risk can help you take preventative action. Hereditary risk can be determined through a genetic test, like GeneMate®. GeneMate® analyzes so-called genomic DNA (gDNA) that contains information about your hereditary risk.
GeneMate® sample collection occurs on your terms, in your home. A sample collection kit is delivered straight to your mailbox with instructions and materials for saliva collection, as well as everything you need to return the sample to iCellate's lab. iCellate performs a comprehensive analysis and breaks down complex information, ultimately providing you with a concrete risk assessment. iCellate's clinical team is available for consultation along the way.
OncoMate® supports oncologists in treatment selection for patients with metastatic disease. Targeted therapies offer high response rates with fewer side effects, and are indicated for cancer patients with certain tumor-driving mutations. Through genomic analysis we help oncologists determine if a patient could benefit from a targeted therapy, and if so, which one.
Circulating tumor DNA (ctDNA) is found in the blood of patients with metastatic cancer. Through liquid biopsy - in other words, a blood biopsy - iCellate sequences ctDNA, performs bioinformatic analysis, and provides a clinical results report. We identify which targetable mutations are present and provide you with concrete treatment options. Our comprehensive gene panel covers all genes for which a variant (mutation) indicates an approved targeted therapy.
OncoMate® is minimally invasive and does not rely on the availability of tumor tissue. OncoMate® expands access to genetic analysis for cancer patients.
KEEP ME IN THE LOOP
Personal cancer screening
The earlier a cancer is detected, the greater the chance of effective treatment and overall survival. Screening of asymptomatic patients can aid in early detection, but many cancer types lack effective screening methods. Today's screening programs are organ-specific, such as mammography for breast cancer or PSA testing for prostate cancer.
CellMate® is used for identification of circulating tumor cells (CTCs) in the blood. CTCs can circulate in the blood up to 12 years before clinical symptoms arise. In two large clinical studies, iCellate has demonstrated CellMate®'s ability to identify CTCs in asymptomatic individuals.
What does a positive CTC finding indicate? Explore further via our FAQs.
KEEP ME IN THE LOOP